Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism.
OBJECTIVE
GH-deficient women using oral estradiol treatment require higher doses of recombinant human GH (rhGH) to achieve similar IGF-I levels when compared with men and women on transdermal estradiol replacement. The aim of this study was to evaluate the effects of oral versus transdermal estrogen administration at similar plasma estradiol levels on IGF-I, IGF-binding protein-3, and sex hormone-binding globulin (SHBG) concentrations.


METHODS
Parallel crossover study in which two groups of hypogonadal and GH-deficient women with fixed and stable rhGH replacement passed through four different estradiol treatment schemes (2 and 4 mg oral, and 50 and 100 microg transdermal estradiol) with a duration of four cycles each to ensure a new steady state. Group I (18 patients using oral estradiol prior to the study) was treated with oral followed by transdermal estradiol and group II (five patients with transdermal estradiol prior to inclusion) with transdermal followed by oral estradiol.


RESULTS
Estradiol concentrations were lowest during 50 microg transdermal and highest during 4 mg oral estradiol treatment. Estradiol concentrations did not differ during 100 microg transdermal and 2 mg oral treatment. Nevertheless, IGF-I levels were significantly higher during 100 microg transdermal when compared with 2 mg oral treatment (P=0.005 in group I and 0.02 in group II), while SHBG levels were significantly lower (P=0.002 in group I and P=0.004 in group II). SHBG and IGF-I concentrations were negatively correlated (R=-0.41, P=0.0001).


CONCLUSIONS
During fixed GH replacement, the route of estrogen administration is a determinant of IGF-I levels in hypogonadal GH-deficient women.
van der Klaauw
Agatha A
AA
Department of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands. a.a.van_der_klaauw@lumc.nl
Biermasz
Nienke R
NR
Zelissen
Pierre M J
PM
Pereira
Alberto M
AM
Lentjes
Eef G W M
EG
Smit
Johannes W A
JW
van Thiel
Sjoerd W
SW
Romijn
Johannes A
JA
Roelfsema
Ferdinand
F
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D004394:Dydrogesterone / Q000008:administration & dosage; D004958:Estradiol / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy*; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012738:Sex Hormone-Binding Globulin / Q000032:analysis
D004967:Estrogens; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D012738:Sex Hormone-Binding Globulin; D019382:Human Growth Hormone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D004394:Dydrogesterone